EPS for OpGen, Inc. (OPGN) Expected At $-0.53

October 13, 2018 - By olga

OpGen, Inc. (NASDAQ:OPGN) Logo

Analysts expect OpGen, Inc. (NASDAQ:OPGN) to report $-0.53 EPS on November, 6.They anticipate $1.22 EPS change or 69.71 % from last quarter’s $-1.75 EPS. After having $-0.57 EPS previously, OpGen, Inc.’s analysts see -7.02 % EPS growth. The stock increased 1.04% or $0.02 during the last trading session, reaching $1.95. About 103,429 shares traded or 13.33% up from the average. OpGen, Inc. (NASDAQ:OPGN) has declined 76.24% since October 14, 2017 and is downtrending. It has underperformed by 91.86% the S&P500.

OpGen, Inc., a precision medicine company, engages in developing molecular information services and products to combat infectious diseases in the healthcare industry worldwide. The company has market cap of $12.11 million. The firm utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It currently has negative earnings. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

More news for OpGen, Inc. (NASDAQ:OPGN) were recently published by: Nasdaq.com, which released: “OpGen to Present at Two Upcoming Investment Conferences in October” on September 25, 2018. Bizjournals.com‘s article titled: “OpGen signs deal with New York health department to research superbugs” and published on September 24, 2018 is yet another important article.

OpGen, Inc. (NASDAQ:OPGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>